The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

Introduction <br/> Helminth infection may affect vaccine immunogenicity and efficacy. Adolescents, a target population for tuberculosis booster vaccines, often have a high helminth burden. We investigated effects of Schistosoma mansoni (Sm) on the immunogenicity and safety of MVA85A, a model c...

Full description

Bibliographic Details
Main Authors:	Wajja, A, Kizito, D, Nassanga, B, Nalwoga, A, Kabagenyi, J, Kimuda, S, Galiwango, R, Mutonyi, G, Vermaak, S, Satti, I, Verweij, J, Tukahebwa, E, Cose, S, Levin, J, Kaleebu, P, Elliott, A, McShane, H
Other Authors:	Diemert, D
Format:	Journal article
Language:	English
Published:	Public Library of Science 2017

Similar Items

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
by: Anne Wajja, et al.
Published: (2017-05-01)

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
by: Wajja, A, et al.
Published: (2018)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
by: Wajja, A, et al.
Published: (2024)

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A [version 1; referees: 1 approved, 2 approved with reservations]
by: Anne Wajja, et al.
Published: (2018-09-01)

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
by: Wajja, A, et al.
Published: (2023)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
by: Mcshane, H
Published: (2008)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
by: Rowland, R, et al.
Published: (2012)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Whelan, K, et al.
Published: (2009)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
by: Harris, S, et al.
Published: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
by: Harris, S, et al.
Published: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
by: Harris, SA, et al.
Published: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
by: Minhinnick, A, et al.
Published: (2016)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
by: Pathan, A, et al.
Published: (2012)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
by: Mcshane, H, et al.
Published: (2005)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
by: Pathan, A, et al.
Published: (2012)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
by: Scriba, T, et al.
Published: (2011)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
by: Fletcher, H, et al.
Published: (2008)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
by: Sheehan, S, et al.
Published: (2015)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
by: Thomas, Z, et al.
Published: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
by: Satti, I, et al.
Published: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
by: Satti, I, et al.
Published: (2014)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
by: Owiafe, P, et al.
Published: (2012)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
by: Rowland, R, et al.
Published: (2013)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
by: de Cassan, S, et al.
Published: (2010)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Published: (2011-01-01)

A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults
by: Fredsgaard-Jones, T, et al.
Published: (2024)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
by: Tameris, M, et al.
Published: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
by: Tameris, M, et al.
Published: (2014)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
by: Tameris, MD, et al.
Published: (2013)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial
by: Tameris, MD, et al.
Published: (2013)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
by: de Cassan, S, et al.
Published: (2011)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG immunized adults vaccinated with a new tuberculosis vaccine, MVA85A (Clinical and Vaccine Immunology (2010) 17, 7, (1066-1073))
by: De Cassan, S, et al.
Published: (2011)

A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults
by: Timothy Fredsgaard-Jones, et al.
Published: (2024-11-01)

Correction: MVA.85A Boosting of BCG and an Attenuated, Deficient Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques.
by: Frank A. W. Verreck, et al.
Published: (2011-01-01)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
by: Michele Tameris, et al.
Published: (2014-01-01)

Vaccination against tuberculosis: how can we better BCG?
by: Pitt, J, et al.
Published: (2013)

Vaccination against tuberculosis: How can we better BCG?
by: Pitt, J, et al.
Published: (2013)

The humoral immune response to BCG vaccination
by: Tanner, R, et al.
Published: (2019)

Optimisation of a human BCG challenge model
by: Wilkie, M, et al.
Published: (2015)